Amgen profit beats estimates, weight-loss data due by year-end

Investing.comTuesday, November 4, 2025 at 10:18:27 PM
Amgen profit beats estimates, weight-loss data due by year-end
Amgen has reported profits that exceed expectations, showcasing strong financial performance. Additionally, the company is set to release important weight-loss data by the end of the year, which could further impact its market position.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Amgen Q3 2025 slides: Revenue up 12%, guidance raised on strong product performance
PositiveFinancial Markets
Amgen has reported a 12% increase in revenue for Q3 2025, prompting the company to raise its guidance due to strong product performance. This positive trend highlights the effectiveness of their strategies and the growing demand for their offerings.
AMD forecasts fourth-quarter revenue above estimates on strong AI chip demand
PositiveFinancial Markets
AMD has announced that it expects its fourth-quarter revenue to exceed estimates, driven by strong demand for its AI chips. This positive outlook reflects the growing interest in artificial intelligence technologies and positions AMD favorably in the competitive semiconductor market.
Stoke Therapeutics earnings missed by $0.07, revenue topped estimates
NeutralFinancial Markets
Stoke Therapeutics reported earnings that fell short of expectations by $0.07, but their revenue exceeded estimates, indicating a mixed performance in their latest financial results.
Zeta Global shares soar as revenue beats estimates, raises outlook
PositiveFinancial Markets
Zeta Global's shares have surged after the company reported revenue that exceeded expectations and raised its outlook for the future. This positive news has boosted investor confidence and reflects the company's strong performance in the market.
IFF shares rise as third quarter earnings top estimates
PositiveFinancial Markets
IFF's shares have seen a significant rise following their third quarter earnings report, which exceeded analysts' expectations. This positive performance reflects the company's strong market position and effective strategies.
Innospec earnings beat by $0.01, revenue fell short of estimates
NeutralFinancial Markets
Innospec reported earnings that exceeded expectations by $0.01, although their revenue fell short of estimates. This mixed performance highlights the challenges the company faces in meeting market forecasts.
Cricut earnings beat by $0.06, revenue topped estimates
PositiveFinancial Markets
Cricut has reported earnings that exceeded expectations by $0.06, with revenue also surpassing estimates. This positive performance highlights the company's strong market position and growth potential.
Horace Mann Educators earnings beat by $0.26, revenue topped estimates
PositiveFinancial Markets
Horace Mann Educators has reported impressive earnings that exceeded expectations by $0.26, along with revenue that topped estimates. This positive financial performance highlights the company's strong position in the market.
Latest from Financial Markets
Private-Credit Earnings Ease Investor Concern Over Asset Class’s Health
PositiveFinancial Markets
Apollo CEO Marc Rowan has reassured investors by addressing concerns regarding the health of the private-credit asset class, easing worries and highlighting the stability of the sector.
Private-Credit Earnings Ease Investor Concern Over Asset Class’s Health
PositiveFinancial Markets
Apollo CEO Marc Rowan has reassured investors by addressing concerns regarding the health of the private-credit asset class, easing worries and highlighting the sector's resilience.
Aviat Networks Q1 FY2026 slides: Revenue jumps 21.4%, exceeding expectations
PositiveFinancial Markets
Aviat Networks reported a remarkable 21.4% increase in revenue for Q1 FY2026, surpassing market expectations. This growth highlights the company's strong performance and positive outlook in the telecommunications sector.
Stoke Therapeutics Q3 2025 presentation: strong revenue growth amid clinical progress
PositiveFinancial Markets
Stoke Therapeutics recently presented its Q3 2025 results, showcasing impressive revenue growth alongside significant advancements in its clinical programs. The company's progress highlights its commitment to developing innovative therapies, making it a key player in the biotechnology sector.
Amgen Q3 2025 slides: Revenue up 12%, guidance raised on strong product performance
PositiveFinancial Markets
Amgen has reported a 12% increase in revenue for Q3 2025, prompting the company to raise its guidance due to strong product performance. This positive trend highlights the effectiveness of their strategies and the growing demand for their offerings.
Corsair Q3 2025 slides show strong growth amid missed earnings forecasts
NeutralFinancial Markets
Corsair's Q3 2025 slides indicate a strong growth trajectory, despite missing earnings forecasts. The company is navigating challenges while showcasing resilience in its performance.